{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:36:35Z","timestamp":1772469395030,"version":"3.50.1"},"reference-count":49,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.2217\/fon-2022-0774","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:40:03Z","timestamp":1674042003000},"page":"19-28","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Lisocabtagene maraleucel in the treatment of relapsed\/refractory large B-cell lymphoma"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-8579","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9rique","family":"St-Pierre","sequence":"first","affiliation":[{"name":"Department of Medicine,Division of Hematology\/Oncology & the Robert H. Lurie Comprehensive Cancer Center of Northwestern University,\rChicago,\rIL\r60208,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo I","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Medicine,Division of Hematology\/Oncology & the Robert H. Lurie Comprehensive Cancer Center of Northwestern University,\rChicago,\rIL\r60208,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_3_3_4_1","volume-title":"Cancer Facts & Figures 2022.","year":"2022","unstructured":"Cancer Facts & Figures 2022. American Cancer Society, Atlanta, GA, USA (2022)."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32407-2"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2271-1"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001843"},{"issue":"5","key":"e_1_3_3_15_1","first-page":"309","article-title":"CAR T-cell therapy for relapsed\/refractory non-Hodgkin\u2019s lymphoma: a comprehensive review","volume":"20","author":"St-Pierre F","year":"2022","unstructured":"St-Pierre F , GordonLI. CAR T-cell therapy for relapsed\/refractory non-Hodgkin\u2019s lymphoma: a comprehensive review. Clin. Adv. Hematol. Oncol.20(5), 309\u2013318 (2022).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_3_3_16_1","first-page":"215","volume-title":"Immunotherapy.","author":"Nair R","year":"2021","unstructured":"Nair R , WestinJ. CAR T-cells. In: Immunotherapy.NaingA, HajjarJ (Eds). Springer International Publishing, Cham, Switzerland1342, 215\u2013233 (2021)."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00910-5"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13239"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813101106"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00607-3"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681984"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.15"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-03-900928"},{"issue":"1","key":"e_1_3_3_31_1","first-page":"S4471","article-title":"JCAR017 is a defined composition CAR T cell product with product and process controls that deliver precise doses of CD4 and CD8 CAR T cell to patients with NHL","volume":"130","author":"Ramsborg CG","year":"2017","unstructured":"Ramsborg CG , GuptillP, WeberCet al. JCAR017 is a defined composition CAR T cell product with product and process controls that deliver precise doses of CD4 and CD8 CAR T cell to patients with NHL. Blood130(Suppl. 1), S4471\u2013S4471 (2017).","journal-title":"Blood"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01039-5"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148948"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17971"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02143"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147913"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7062"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00339-4"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.6567"},{"key":"e_1_3_3_45_1","volume-title":"FDA D.I.S.C.O. Burst Edition: FDA Approval of Breyanzi (Lisocabtagene Maraleucel) for Second-Line Treatment of Large B-Cell Lymphoma.","year":"2022","unstructured":"FDA D.I.S.C.O. Burst Edition: FDA Approval of Breyanzi (Lisocabtagene Maraleucel) for Second-Line Treatment of Large B-Cell Lymphoma. US FDA, Silver Spring, MD, USA (2022)."},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00268-z"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7535"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01144-9"},{"issue":"5","key":"e_1_3_3_49_1","first-page":"309","article-title":"CAR T-cell therapy for relapsed\/refractory non-Hodgkin\u2019s lymphoma: a comprehensive review","volume":"20","author":"St-Pierre F","year":"2022","unstructured":"St-Pierre F , GordonLI. CAR T-cell therapy for relapsed\/refractory non-Hodgkin\u2019s lymphoma: a comprehensive review. Clin. Adv. Hematol. Oncol.20(5), 309\u2013318 (2022).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1855140"},{"issue":"11","key":"e_1_3_3_51_1","first-page":"1429","article-title":"Emerging role of CAR T cells in non-Hodgkin\u2019s lymphoma","volume":"15","author":"Avanzi MP","year":"2017","unstructured":"Avanzi MP , BrentjensRJ. Emerging role of CAR T cells in non-Hodgkin\u2019s lymphoma. JNCCN15(11), 1429\u20131437 (2017).","journal-title":"JNCCN"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T19:11:12Z","timestamp":1724353872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.2217\/fon-2022-0774"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0774","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}